Corium International (NASDAQ:CORI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The firm presently has a $13.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 23.22% from the stock’s previous close.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
CORI has been the topic of a number of other research reports. Needham & Company LLC dropped their price objective on Corium International from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, December 26th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a report on Friday, December 22nd. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright set a $14.00 price objective on Corium International and gave the company a “buy” rating in a report on Wednesday, December 27th. Finally, BidaskClub downgraded Corium International from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $13.00.
Shares of CORI traded down $0.92 during mid-day trading on Monday, reaching $10.55. The company’s stock had a trading volume of 419,295 shares, compared to its average volume of 291,660. Corium International has a 12-month low of $4.04 and a 12-month high of $13.93. The company has a market cap of $414.34, a P/E ratio of -6.43 and a beta of 1.59. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40.
Corium International (NASDAQ:CORI) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. The business had revenue of $9.32 million for the quarter, compared to the consensus estimate of $7.48 million. analysts predict that Corium International will post -1.47 earnings per share for the current fiscal year.
In other news, major shareholder Perceptive Advisors Llc bought 50,350 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was purchased at an average cost of $11.83 per share, with a total value of $595,640.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was purchased at an average cost of $12.54 per share, with a total value of $6,395,400.00. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. RTW Investments LP lifted its position in Corium International by 1.4% during the 4th quarter. RTW Investments LP now owns 1,699,653 shares of the biopharmaceutical company’s stock worth $16,334,000 after acquiring an additional 24,174 shares during the period. BlackRock Inc. lifted its position in Corium International by 42.1% during the 4th quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock worth $16,143,000 after acquiring an additional 497,615 shares during the period. Opaleye Management Inc. lifted its position in Corium International by 15.2% during the 4th quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock worth $10,186,000 after acquiring an additional 140,000 shares during the period. Tamarack Advisers LP lifted its position in Corium International by 6.3% during the 4th quarter. Tamarack Advisers LP now owns 1,010,000 shares of the biopharmaceutical company’s stock worth $9,706,000 after acquiring an additional 60,000 shares during the period. Finally, State Street Corp acquired a new stake in Corium International during the 2nd quarter worth approximately $1,840,000. 88.58% of the stock is owned by institutional investors.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.